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Background. This study aimed to identify the course of unmet needs by patients with a ﬁrst episode of
schizophrenia and to determine associated variables.
Method. We investigated baseline assessments in the European First Episode Schizophrenia Trial (EUFEST) and also
follow-up interviews at 6 and 12 months. Latent class growth analysis was used to identify patient groups based on
individual diﬀerences in the development of unmet needs. Multinomial logistic regression determined the predictors
of group membership.
Results. Four classes were identiﬁed. Three diﬀered in their baseline levels of unmet needs whereas the fourth had a
marked decrease in such needs. Main predictors of class membership were prognosis and depression at baseline, and
the quality of life and psychosocial intervention at follow-up. Depression at follow-up did not vary among classes.
Conclusions. We identiﬁed subtypes of patients with diﬀerent courses of unmet needs. Prognosis of clinical im-
provement was a better predictor for the decline in unmet needs than was psychopathology. Needs concerning social
relationships were particularly persistent in patients who remained high in their unmet needs and who lacked
additional psychosocial treatment.
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Introduction
Despite continuing eﬀorts within the framework of
early intervention programmes to identify persons at
risk, the initial contact with mental health services of-
ten coincides with a ﬁrst episode of schizophrenia
(McGorry et al. 1996 ; Klosterko¨tter et al. 2005 ; Lester
et al. 2009 ; Ruhrmann et al. 2010). Early treatment re-
duces the potential for an unfavourable course that
comprises persistent symptoms, (re)hospitalizations
and deﬁcits in social and vocational functioning
(Perkins et al. 2005 ; Addington et al. 2007; Barnes et al.
2008 ; de Koning et al. 2009 ; Farooq et al. 2009 ;
McGorry et al. 2010). First-episode patients beneﬁt
from a treatment approach that decreases psycho-
pathological symptoms but also focuses on psycho-
social functioning (Penn et al. 2005). In many cases,
such functioning has already deteriorated before the
exacerbation of the ﬁrst psychosis ; in young people,
psychosocial development is impaired by the illness
and those persons remain at a low level of functioning
(Ha¨fner et al. 1999). Most of the negative changes in
social disability attributed to schizophrenia occur in
the ﬁrst 2–5 years of illness (an der Heiden & Ha¨fner,
2000). Thus, stopping this process is a core component
of successful treatment (an der Heiden & Ha¨fner,
2000). One way to develop better treatment strategies
is to monitor changes in treatment needs over time
and to identify the conditions under which they arise.
Assessing treatment needs is an established element
of clinical practice and service evaluation. In this con-
text, needs are deﬁned as the potential to beneﬁt from
(mental) health care (Wiersma, 2006), that is reversing
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a deﬁcit by treatment. A more realistic deﬁnition states
that needs are the prerequisite for maintaining or re-
storing an acceptable level of social independence and
quality of life (McCrone et al. 2001). The concept of
needs has been criticized because it presupposes an
eﬀective, but general, treatment that works for every
patient with a given diagnosis, and for confounding
the identiﬁcation of a need with its potential solution
(Priebe et al. 1999a). Nevertheless, the widespread use
of needs assessment in research and practice calls for
critical appraisal.
Several interviews for assessing needs for care
have been developed. The most commonly applied are
the Needs for Care Assessment (NCA; Brewin et al.
1987) and the Camberwell Assessment of Need (CAN;
Phelan et al. 1995). The NCA includes an elaborate
evaluation of psychopathology and psychosocial
status. The NCA and its revised form, the Cardinal
Needs Schedule (CNS; Marshall et al. 1995), are more
extensive than the CAN, and hence the latter is gen-
erally used in larger studies (Kilian et al. 2001).
The CAN inquires about 22 potentially problematic
areas of living, and diﬀerentiates among (1) ‘met
needs’ (patient has a speciﬁc need and this need is met
by treatment), (2) ‘unmet needs’ (speciﬁc needs that
are not met by treatment), and (3) ‘no needs’ (patient
does not have a need in this area of living). Several
attempts have been made to establish groupings of the
CAN items. However, the results from studies using
data reduction techniques have been inconsistent
(Wennstro¨m et al. 2004; Korkeila et al. 2005) and none
of the factor solutions have become widely accepted or
replicated. Here, we propose an alternative approach
in which several classes of patients are identiﬁed who
show diﬀerent trajectories of needs over time.
Most research using the CAN considers only
patients with a chronic or well-established illness. Our
study is the ﬁrst to adopt that approach in determining
needs within ﬁrst-episode schizophrenia. Treatment of
acute episodes can be divided into three phases. The
acute phase (weeks or a few months) is followed by a
post-acute stabilization phase (3–6 months), and then
by a stable phase of (partial) remission (months to
years) (DGPPN, 2006). All of these phases should be
examined when evaluating the progression of needs in
ﬁrst-episode patients over time.
Aims of the study
Three questions are addressed by the present study:
(1) What is the course of needs over a 12-month
period in ﬁrst-episode patients compared with
chronic schizophrenia patients?
(2) Can we identify clusters of patients with diﬀerent
trajectories of unmet needs?
(3) If so, what are the variables associated with those
trajectories?
Method
Database
Our study used data from the European First
Episode Schizophrenia Trial (EUFEST; Fleischhacker
et al. 2005 ; Kahn et al. 2008). In the EUFEST, four
second-generation antipsychotics (amisulpride, 200–
800 mg; olanzapine, 5–20 mg; quetiapine, 200–
750 mg; and ziprasidone, 40–160 mg) were compared
against each other and against treatment with a low
dose of haloperidol (1–4 mg) (Kahn et al. 2008). The
main outcome measure was 1-year medication reten-
tion rates, that is the proportion of patients who con-
tinued with the same medication and the same initial
dosage. In addition, a battery of outcome and diag-
nostic measures was assessed at deﬁned time points
for all patients who did not withdraw informed con-
sent or drop out for other reasons. The present study
investigated a selection of those measures.
Sample
Fifty mental health centres in 13 European countries
and Israel were selected for participation. Altogether,
1047 patients were screened for eligibility between
December 2002 and January 2006. Inclusion criteria
were ages 18–40 years ; a DSM-IV diagnosis of schizo-
phrenia, schizophreniform disorder or schizo-aﬀective
disorder ; onset of positive symptoms dating back f2
years ; use of antipsychotic drugs forf2 weeks in the
previous year or for f6 weeks at any time; and no
known intolerance or contraindication for one of the
study drugs. Diagnoses were conﬁrmed by the Mini
International Neuropsychiatric Interview (MINI-Plus ;
Sheehan et al. 1998). In all, 498 patients gave informed
consent and were randomly assigned to ﬁve treatment
groups. The study protocol was evaluated by local
ethics committees or review boards according to
country-speciﬁc laws.
Attrition rate
Attrition was not similar to loss of retention of the
study drug because patients were followed up beyond
loss of retention. Of the 498 patients initially included,
342 (68.7%) completed the assessments scheduled
by the study according to protocol. Of the 156 with-
drawals (31.3% of the baseline total sample), in-
vestigators withdrew six, and another four did not
meet the inclusion criteria. The remaining 146 patients
decided by themselves not to continue the study by
withdrawal of consent or no-show. Fig. 1 presents an
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adapted ﬂow chart for the sample used in our analyses
(shaded boxes). More details about the entire trial are
included within the main EUFEST paper (Kahn et al.
2008).
Measures
Met and unmet needs were evaluated according to
the CAN (Phelan et al. 1995), which assesses ratings
by patients and also by therapists, case-workers or
research assistants. Because scores can diﬀer substan-
tially between patients and professionals, it is import-
ant to consider whose perspective is reported when
needs are discussed (Slade et al. 1996, 1998 ; Issakidis
& Teesson, 1999 ; Priebe et al. 1999a ; Lasalvia et al.
2000 ; Hansson et al. 2001; Macpherson et al. 2003 ;
Wennstro¨m & Wiesel, 2006 ; Wiersma, 2006). Validity
and reliability were previously established in several
studies and deemed acceptable (Phelan et al. 1995). In
the original paper, inter-rater reliability was r=0.99
(patients) and r=0.98 (staﬀ), and test–retest reliability
between r=0.78 (patients) and r=0.71 (staﬀ) (Phelan
et al. 1995). However, test–retest reliability was not
adequate for some single items (Kilian et al. 2001), but
this could be due to skewed distributions of the re-
spective items (Phelan et al. 1995).
We also used the Positive and Negative Syndrome
Scale (PANSS; Kay et al. 1987), the Manchester
Short Assessment of Quality of Life (MANSA;
Priebe et al. 1999b), the Calgary Depression Scale for
Schizophrenia (CDSS; Addington et al. 1993) and the
Global Assessment of Functioning (GAF; Jones et al.
1995). In addition, the Hayward Scale assessed com-
pliance (a one-item seven-point rating scale, with
higher scores suggesting better adherence ; Kemp et al.
1998), and prognosis was evaluated along a six-point
scale that ranged from 1=best to 6=bad.
The PANSS measures positive and negative symp-
toms and the general psychopathology of schizo-
phrenia. Consisting of 30 items, it is scored by
a trained rater during a structured interview of
30–40 min. Leucht et al. (2005) proposed that a re-
duction of 50% (respectively of 25% in treatment-
refractory patients) indicates treatment success.
We used the 50% criterion, even though the exact
level of symptom reduction indicating response has
been debated (e.g. Kinon et al. 2008), because this
was only used to describe the sample. The percentage
reduction was calculated after subtracting 30
(the minimal score) from the PANSS sum score.
The CDSS, a nine-item scale, measures the level of
depression in schizophrenia with good reliability
(Addington et al. 1992). A cut-oﬀ of seven points re-
fers to a speciﬁcity of 82% and a sensitivity of 85% for
detecting major depressive episodes (Addington et al.
1993).
1047 patients assessed for 
eligibility
549 ineligible
498 patients randomised
207 patients discontinued
study drug (loss of retention)
144 patients completed
follow-up (69.6%)
198 patients completed 
follow-up (68.8%)
• 57 patient withdrawal
• 1 inclusion criteria not met
• 5 investigator withdraws 
patient
93 patients lost to follow-up 
(31.2%)
63 patients lost to follow-up
(30.4%)
• 89 patient withdrawal
• 3 inclusion criteria not met
• 1 investigator withdraws 
patient
291 patients continued study
drug until-drop out of follow-
up
• 103 haloperidol
• 104 amisulpride
• 105 olanzapine
• 104 quetiapine
• 82 ziprasidone
• 110 insufficient efficacy
• 38 side effects
• 58 non-compliance
• 1 other reason
Fig. 1. Simpliﬁed ﬂow chart to illustrate the sample used here. Shaded boxes indicate 342 patients who completed the study
according to our protocol (but independently of the trial randomization) and thus were included in the present analyses.
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The 14 participating countries were clustered
into two regions : West European (The Netherlands,
Belgium, France, Switzerland, Austria, Germany,
Sweden, Spain and Italy) and East and Central
European (Bulgaria, Poland, Romania and Czech
Republic). Because only a few patients were from
Israel, that country was added to the West European
category to control for cell sizes and conﬁdence inter-
vals in the analyses.
Sociodemographic variables were assessed at the
beginning of the study (baseline, 0 months). At each
assessment, relapse and psychosocial interventions
were described. Episodes of psychosocial treatment
were recorded with beginning and ending dates.
Compliance with medication was measured at 1, 6
and 12 months. All other measures were assessed at
least at baseline, 6 and 12 months1#. Observer-rated
measures were assessed by site coordinators or co-
investigators, for example psychiatrists (including
trainees), research nurses or psychologists.
Statistical analyses
The analyses were preceded by a comparison between
the baseline sample characteristics of completers
and the baseline characteristics of the complete sam-
ple. We used SPSS (PASW Statistics 18.0 for Windows)
to calculate t tests for continuous variables (or the non-
parametric equivalent Mann–Whitney test for vari-
ables with non-normal distributions) and x2 statistics
for categorical variables.
Because we were interested in individual trajec-
tories of unmet needs over three time points, we de-
veloped a latent class growth model using Latent Gold
4.5. This modelling technique identiﬁes diﬀerent types
of patients by estimating continuous latent variables
for individual intercepts and slopes, in addition to a
categorical latent variable that represents groups with
similar trajectories (Nagin, 1999). The analysis was
based on the sum score of unmet needs. Our aim was
to identify groups of patients as determined by maxi-
mally distinct trajectories of needs between groups
and minimally distinct individual trajectories within
groups. The number of groups was obtained statisti-
cally by comparing the model-ﬁt indices of models
with successive numbers of clusters. Because data
were sparse, model signiﬁcance (p value associated)
with the L2 ﬁt statistic was assessed using the boot-
strap option within Latent Gold 4.5 rather than with
standard x2 values. Model ﬁt was based upon the
Bayesian Information Criterion (BIC). To decide on the
ﬁnal model, statistical ﬁt indices were supplemented
by the criteria of suitability for answering the research
question, parsimony, theoretical justiﬁcation, and in-
terpretability (Muthe´n & Muthe´n, 2000). The sum of
unmet needs was deﬁned as a count variable.
Finally, we determined the predictors of member-
ship for latent clusters of unmet-needs trajectories
and the outcomes of clusters. Although Latent Gold
4.5 allows predictors to be included directly, that op-
tion is restricted to categorical variables. Because
the measures used in this EUFEST study were count,
ordered-categorical or continuous, we preferred a
multinomial logistic regression with cluster member-
ship as the dependent variable. In the bivariate multi-
nomial regressions, associated variables were selected
on the basis of their signiﬁcance (p<0.1 to consider
weak eﬀects also). Positive and negative symptoms,
insight (one item from the PANSS), gender, region,
and age were included by default. In the outcome
model, follow-up values for the same longitudinal
variables were used, and information was added for
the number of relapses and psychosocial intervention
(duration ofo1 month). In the combined multinomial
regression model, variables with a signiﬁcant Likeli-
hood Quotient Test (LQT; p<0.05) were considered
main inﬂuences. Those that discerned only one group
from another due to a signiﬁcant odds ratio, but
without any signiﬁcant LQT, are also discussed.
Multinomial regression was calculated with SPSS.
Diﬀerences in single needs that arose between as-
sessment periods were not subjected to statistical
testing because of limited cell sizes.
Results
Sample characteristics
The sample of study completers was used in our
analyses. The mean age was 26.1 years at baseline, and
more men (56.4%) participated than women (Table 1).
More than half of the sample (59.6%) was from Central
and East European countries. Paranoid schizophrenia
(45.3%) and schizophreniform disorder (40.1%) were
the most prevalent diagnostic categories.
Signiﬁcant, but not large, dropout eﬀects (dif-
ferences in baseline scores between completers and
dropouts) were found for the following variables :
gender (more male dropouts), region (fewer dropouts
in East and Central European countries), treatment
compliance (more adherent patients completed the
study), and prognosis (completers had a better prog-
nosis). Finally, completers had more met and unmet
needs at baseline than did dropouts.
From baseline to 12 months of follow-up, 78.7%
(263 of 334 completers) reached a 50% reduction in
their PANSS total scores. At baseline, 36.1% (123/341)
had a diagnosis of major depression according to
the CDSS score ; at 12 months, this was only 3.5%# The notes appear after the main text.
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(12/340). Most subjects were part of in-patient treat-
ment settings at the beginning of the study (89.8%;
307/342) versus only 4.7% (16/340) at the 12-month
follow-up. About 32.5% of the patients (111/342)
had received some psychosocial treatment for at least
1 month.
Figure 2 depicts the course of patient-rated met
and unmet needs, measured by the CAN. Both clearly
decreased from baseline to 6 months. Whereas the
number of met needs continued to decline in the sec-
ond half of the study, the amount of unmet needs
tended to remain stable over that period. Compared
with baseline ﬁndings, at 12 months 65.0% (n=208)
patients had fewer unmet needs, 27.5% had an equal
number, and 7.5% (24) had more. At baseline, met
needs were slightly more frequent than unmet needs
(ratio met/unmet=1.41), but after 6 and 12 months,
at least two out of three needs were met (ratio met/
unmet=2.41 and 1.96 respectively) (Fig. 2).
Diﬀerences in the course of unmet needs between
patient classes
A four-class model describing the course of unmet
needs best ﬁtted the data (Fig. 3). This solution ful-
ﬁlled other criteria of model usability, being practical
and easy to explain (Muthe´n & Muthe´n, 2000). Class 1
(autonomous group) had few unmet needs and a dim-
inishing trend between baseline and 6 months. A sec-
ond started with a mean of 2.5 unmet needs, then
declined sharply to 1.25 from baseline to 6 months and
slowly to 1.15 afterwards (ordinary group, class 2).
Our uncomplicated group (class 3) started with 4.5
unmet needs, then markedly decreased to nearly zero
unmet needs in the ﬁrst 6 months before showing no
other change. Finally, class 4 (complicated group) be-
gan with nearly 5.0 unmet needs at baseline, which
distinctly dropped to 3.75 at 6 months before increas-
ing to 4.0 unmet needs by month 12.
Table 1. Descriptive statistics of selected variables at baseline (total sample, n=498) and sample of completers (n=342)
Baseline total Baseline completers Dropouts
Diﬀerencea
Mean¡S.D./% n Mean¡S.D./% n Mean¡S.D./% n p
Age at baseline (years) 25.98¡5.55 (498) 26.05¡5.64 (342) 25.83¡5.38 (156) 0.618
Gender (women) 40.2 (200) 43.6 (149) 32.7 (51) 0.024
Cultural region 0.000
West Europe 34.9 (174) 28.9 (99) 48.1 (75) –
East/Central Europe 51.4 (256) 59.6 (204) 33.3 (52) –
Israel 13.7 (68) 11.4 (39) 18.6 (29) –
Occupation at baseline (yes) 46.6 (231) 46.5 (159) 46.8 (72) 1.000
Antipsychotic naive at baseline 32.5 (162) 30.7 (105) 36.5 (57) 0.216
DSM-III-R diagnosis 0.603
Disorganized, catatonic,
undiﬀerentiated
8.4 (42) 7.3 (25) 10.9 (17) –
Paranoid 44.8 (223) 45.3 (155) 43.6 (68) –
Schizophreniform 39.8 (198) 40.1 (137) 39.1 (61) –
Schizo-aﬀective 7.0 (35) 7.3 (25) 6.4 (10) –
Met needs patient, sum 2.59¡2.57 (470) 2.78¡2.73 (333) 2.15¡2.06 (137) 0.007/0.034
Unmet needs patient, sum 2.04¡2.07 (470) 2.19¡2.14 (333) 1.66¡1.82 (137) 0.012/0.013
MANSA 4.04¡0.92 (483) 3.98¡0.90 (339) 4.19¡0.96 (144) 0.023/0.022
GAF 40.03¡13.51 (490) 40.72¡13.50 (341) 38.46¡13.44 (149) 0.087/0.107
PANSS total score 88.53¡20.63 (487) 89.06¡20.69 (340) 87.29¡20.49 (147) 0.386/0.371
PANSS positive symptoms 23.13¡6.19 (489) 23.36¡6.17 (340) 22.59¡6.23 (149) 0.205/0.138
PANSS negative symptoms 21.23¡7.62 (489) 21.14¡7.73 (341) 21.42¡7.41 (148) 0.714/0.793
CDSS, sum score 5.07¡4.87 (488) 5.27¡4.88 (341) 4.62¡4.84 (147) 0.176/0.140
Prognosis by investigators 3.19¡1.19 (495) 3.10¡1.18 (342) 3.39¡1.19 (153) 0.014/0.014
Compliance (at 1 month) 5.57¡1.20 (453) 5.66¡1.16 (337) 5.30¡1.29 (116) 0.006/0.006
MANSA, Manchester Short Assessment of Quality of Life ; GAF, Global Assessment of Functioning ; PANSS, Positive and
Negative Syndrome Scale ; CDSS, Calgary Depression Scale for Schizophrenia ; S.D., standard deviation.
a Dropouts – completers : signiﬁcance of diﬀerences between baseline completers and dropouts was calculated for each
continuous/count/ordinal variable with t tests (ﬁrst p value), to control for non-normal distributions with the Mann–Whitney
test (second p value), and with x2 tests for nominal variables.
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When the ratio of met to unmet needs was con-
sidered, change in the ﬁrst 6 months was greatest in
the uncomplicated group, that is from a ratio of 0.74 at
baseline, the ratio increased to 4 met needs for every 1
unmet need (n=2). By contrast, ratios for the compli-
cated class remained relatively stable over the three
time points (0.80, 1.51, 1.37).
Predictors and outcomes of needs course
Covariates of the course of unmet needs that were
signiﬁcant at p<0.1 in bivariate analysis were com-
bined in one multinomial regression model. Positive
and negative symptoms in addition to the item ‘in-
sight ’ from the PANSS were included by default.
Table 2 shows our results from the multinomial re-
gression analysis of baseline variables. The auton-
omous group was chosen as the reference class.
From our model, the signiﬁcant predictors at baseline
were depression (means : class 1=4.17, class 2=5.25,
class 3=8.00, class 4=6.51), prognosis (class 1=2.92,
class 2=3.43, class 3=2.93, class 4=3.60), age (class
1=25.78, class 2=27.26, class 3=25.06, class 4=26.16),
region (West Europe and Israel, class 1=33.5%, class
2=53.2%, class 3=41.1%, class 4=37.1%) and being
antipsychotic naive (class 1=32.9%, class 2=26.0%,
class 3=39.3%, class 4=14.3%) according to the LQT
(p<0.05). Patients in the ordinary group had less
favourable prognoses than those in the reference
group. Persons with an uncomplicated course were
distinguished from the autonomous group only by
higher depression scores and lower quality of life at
baseline. Patients with a complicated-needs course
were more often male, had higher baseline depression
scores, a less favourable prognosis, and lower com-
pliance. Moreover, they included more patients who
had already used antipsychotic medication before the
study began. Prognosis at baseline indirectly sep-
arated the complicated from the uncomplicated group.
Values for variables used in the baseline model (age,
region and gender) were included in the follow-up
model (Table 2), as were the number of relapses and
psychosocial intervention (duration of o1 month).
Psychosocial interventions (class 1=35.3%, class
2=42.9%, class 3=25.0%, class 4=11.4%) and quality
of life (class 1=5.06, class 2=4.66, class 3=4.82, class
4=4.16) were signiﬁcant covariates in the model
(LQT p<0.05). None of the follow-up variables diﬀer-
entiated between the autonomous (reference) and the
ordinary group. The uncomplicated group had lower
functioning scores at follow-up compared with the
reference group. The complicated group had fewer
psychosocial interventions, lower quality of life, more
positive symptoms, fewer negative symptoms, and
better compliance than did the autonomous group
(Table 2).
3.0
2.5
2.0
1.5
1.0
0.5
0
T1 T7 T9
Mean number of met needs
Mean number of unmet needs
Mean ratio met needs/unmet needs
Fig. 2.Means for number of met needs, unmet needs, and
ratios for met needs/unmet needs according to patient
ratings from baseline (T1) to 6 months (T7) and 12 months
(T9) in the European First Episode Schizophrenia Trial
(EUFEST). All patients providing Camberwell Assessment of
Need (CAN) ratings at the respective assessments were
included. If a person indicated no unmet needs, the
respective case was set to the ‘ system missing ’ value.
Therefore, the sample from ratios is much smaller than the
sample used for sum scores.
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
T1 T7 T9
Class 1 “autonomous” (50.3%)
Class 2 “ordinary” (22.8%)
Class 3 “uncomplicated” (16.6%)
Class 4 “complicated” (10.4%)
Fig. 3. Four-class model of sum of unmet-need patient ratings
(total n=338). The lines represent the mean number of unmet
needs in each class. The four-class model was selected
according to the Bayesian Information Criterion (BIC). Class
sizes were n (class 1)=170, n (class 2)=77, n (class 3)=56,
n (class 4)=35. T1, baseline ; T7, 6 months ; T9, 12 months.
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Speciﬁc unmet needs
In all four classes, daytime activities, psychotic symp-
toms, psychological distress and social integration
were most often rated as unmet needs (Fig. 4a). In
areas of life where unmet needs were prevalent at
baseline, some still remained unmet after 12 months.
Met needs (Fig. 4a) were more persistent, being
Table 2. Baseline and follow-up covariates of unmet needs by diﬀerent trajectory classes (total n=331 at baseline and n=327 at
follow-up). Reference class : Class 1 ‘autonomous ’ (n=167)a,b
Class 2 ‘ordinary ’ Class 3 ‘uncomplicated ’ Class 4 ‘ complicated ’
OR (95% CI) OR (95% CI) OR (95% CI)
Baseline
GAF functioning 0.99 (0.97–1.01) 0.98 (0.95–1.00) 0.97 (0.93–1.01)
CDSS depression score 1.04 (0.97–1.11) 1.14 (1.06–1.23) 1.13 (1.02–1.25)
MANSA quality of life 0.70 (0.49–1.01) 0.63 (0.41–0.97) 0.60 (0.36–1.02)
PANSS positive symptoms 1.00 (0.94–1.06) 1.04 (0.97–1.11) 0.95 (0.86–1.04)
PANSS negative symptoms 0.99 (0.95–1.03) 0.96 (0.92–1.01) 0.95 (0.89–1.01)
PANSS insight 1.02 (0.80–1.31) 0.86 (0.64–1.15) 0.81 (0.55–1.18)
Prognosisc 1.33 (1.03–1.73) 1.07 (0.78–1.47) 1.74 (1.16–2.60)
Compliance 1 month 0.92 (0.69–1.22) 0.99 (0.70–1.39) 0.62 (0.42–0.92)
Age 1.05 (1.00–1.10) 0.96 (0.90–1.03) 0.99 (0.91–1.07)
Men (ref.)d
Women 0.55 (0.30–0.95) 0.69 (0.35–1.38) 0.35 (0.14–0.89)
East/Central Europe (ref.)
West Europe 1.85 (0.98–3.48) 1.12 (0.54–2.33) 0.37 (0.13–1.09)
Occupation yes (ref.)
Occupation no 1.41 (0.76–2.63) 1.07 (0.53–2.16) 2.37 (0.86–6.55)
Not naive (ref.)
Naive 0.60 (0.31–1.16) 1.09 (0.54–2.21) 0.20 (0.06–0.68)
Follow-up
GAF functioning 0.98 (0.95–1.01) 0.97 (0.93–1.00) 0.96 (0.92–1.00)
CDSS depression score 1.03 (0.88–1.20) 0.97 (0.80–1.17) 1.15 (0.94–1.41)
MANSA quality of life 0.67 (0.42–1.07) 0.68 (0.40–1.13) 0.30 (0.15–0.60)
PANSS positive symptoms 1.10 (0.99–1.22) 1.09 (0.97–1.23) 1.15 (1.01–1.31)
PANSS negative symptoms 0.95 (0.89–1.02) 0.93 (0.87–1.01) 0.89 (0.80–0.98)
PANSS insight 1.02 (0.73–1.41) 0.76 (0.51–1.13) 0.91 (0.56–1.49)
Compliance 1.22 (0.97–1.53) 1.11 (0.86–1.42) 1.49 (1.05–2.13)
Psychosocial intervention, yes (ref.)
No 1.05 (0.53–2.31) 1.98 (0.89–4.42) 5.82 (1.51–22.50)
Number of relapses 1.34 (0.72–2.49) 0.98 (0.46–2.09) 1.31 (0.58–2.98)
Age 1.04 (0.99–1.10) 0.97 (0.91–1.04) 0.98 (0.90–1.06)
Men (ref.)
Women 0.60 (0.32–1.12) 0.84 (0.43–1.65) 0.38 (0.14–1.00)
East/Central Europe (ref.)
West Europe 1.84 (0.53–2.06) 1.39 (0.62–3.07) 1.02 (0.33–3.09)
GAF, Global Assessment of Functioning ; CDSS, Calgary Depression Scale for Schizophrenia ; MANSA, Manchester Short
Assessment of Quality of Life ; PANSS, Positive and Negative Syndrome Scale ; OR, odds ratio ; CI, conﬁdence interval.
Bold ﬁgures indicate signiﬁcance at p<0.05.
a According to the Likelihood Quotient Test (LQT), the omitting of region, CDSS, being antipsychotic naive at baseline, and
prognosis led to signiﬁcantly diﬀerent models (p<0.05). Overall model ﬁt : x2 118.066, degrees of freedom (df) 39, p<0.000.
Pseudo R2 : Cox & Snell 0.300, Nagelkerke 0.329, McFaden 0.148.
b According to the LQT, only the omissions of MANSA and psychosocial intervention led to signiﬁcantly diﬀerent models.
Overall model ﬁt : x2 104.402, df 36, p<0.000. Pseudo R2 : Cox & Snell 0.273, Nagelkerke 0.300, McFaden 0.131.
c Prognosis is inversely scored : higher scores mean a more unfavourable prognosis.
d Reference category. This parameter is set to zero because it is redundant.
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associated with hardly any reduction in psychotic
symptoms and social integration. Figure 4b depicts the
change in speciﬁc unmet needs for each class. A bar
corresponds to the total change in a particular item in
the total sample (=100%). Each bar contains infor-
mation on change in the four classes. The negative
section of the bars represents fewer unmet needs
at 12 months than at baseline whereas the positive
portion corresponds to an augmentation in unmet
needs. For example, ‘ intimate relationship’ : change in
class 1=x6, change in class 2=x1, change in class
3=x18, change in class 4=+7; total change in unmet
needs=28 (100%).
Those needs concerning self-care, sexual ex-
pression, education and transport became more fre-
quent in the ordinary group whereas those related to
sexual expression, intimate relationship, company,
education, looking after home, and money became
more frequent in the complicated group.
Discussion
Information is scarce about the course of treatment
needs for persons in the early stages of schizophrenia.
We analysed patient ratings of needs over a 12-month
span in a homogeneous sample of participants suﬀer-
ing from ﬁrst-episode schizophrenia. It became clear
that the ﬁrst 6 months were of outmost importance to
treatment because the largest proportion of change in
needs occurred during that period.
The EUFEST sample contains many relatively well-
integrated patients who possibly will never become
chronically ill. Accordingly, the degree of reduction in
unmet needs over time has proven more pronounced
in that study than in other research encompassing the
same time-span in longer established illness (Priebe
et al. 2002). Because the EUFEST sample was homo-
geneous for the phase of illness at baseline, the ma-
jority of patients made a transition from the acute
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Fig. 4. (a) Distribution of needs in detail. Bars represent numbers of met (triangles) and unmet (darker bars) needs at
baseline (T1) ; crosses (met needs) and lighter bars (unmet needs) represent numbers of needs at the 12-month follow-up (T9).
(b) Percentage change between baseline (T1) and 12-month follow-up (T9) in single unmet needs in the four classes. 100%
represents the total change in a particular item in the total sample. The coloured bars represent how much of this change
was present in each of the latent classes. Positive values mean more unmet needs, negative values indicate a reduction in
unmet needs.
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phase of illness to remission after about 6 months.
They then reached the stabilization phase during
the second half of the study. At least at baseline, all
were under neuroleptic medication, which helped to
reduce symptoms and contributed to an initial decline
in unmet treatment needs in the majority of patients.
Neither the duration of medication nor ﬁrst- versus
second-generation neuroleptic medication had a sig-
niﬁcant impact on the course of unmet needs. How-
ever, a ﬂoor eﬀect may have been responsible for the
relatively stable course of unmet needs between 6 and
12 months.
The overall curve of unmet needs was composed
of three groups that diﬀered mainly in their baseline
numbers of unmet needs, plus one relatively small
group that showed a marked decline in those needs.
The largest group had few unmet needs throughout
the study. From the beginning, patients from this
group had better prognoses than those who remained
higher in unmet needs. They also experienced less
depression and a better quality of life than did patient
groups with more initial unmet needs. This group was
called the ‘autonomous’ group because they had
fewer unmet needs, even if they did not have more
psychosocial interventions. The ‘ordinary’ group had
slightly more unmet needs throughout the study
compared with the autonomous group, in addition to
a less favourable initial prognosis. Accordingly, more
patients in this group underwent some type of
psychosocial treatment. Although many of their un-
met needs had disappeared by month 6, those that
concerned education and transport, which might be-
come more important in more stable phases of illness,
had increased. Patients in the ‘uncomplicated group’
had relatively numerous unmet needs at the beginning
but then showed a very steep decline from baseline
until the 6-month assessment, even if they did not
have more frequent psychosocial treatment than the
other two groups. Strong initial depression and low
quality of life might have been reasons for the elevated
number of unmet needs at baseline. Patients in the
‘complicated group’, who had fairly elevated levels
of unmet needs over the entire time-span, had more
initial depression, as was also found with the un-
complicated group. However, they seemed to miss the
opportunity for recovery, as evidenced by their greater
number of positive symptoms at follow-up compared
with other groups. The lack of psychosocial inter-
ventions might have been a reason for this because
patients’ psychosocial needs had increased at the time
of follow-up.
Some processes that inﬂuence the course of unmet
needs merit a closer look. For example, high de-
pression scores at the beginning of our study co-
incided with a high degree of unmet needs. However,
depression did not diﬀer between the uncomplicated
group with declining unmet needs and the compli-
cated group that sustained a high level of such unmet
needs. Because depression during the follow-up
period was no longer associated with various courses
of needs, this ﬁnding cannot be explained by a self-
rating bias of both instruments (Hansson et al. 2007).
Findings that concern predictions of later depressive
episodes based upon depression in the prodromal or
acute states are unequivocal (an der Heiden & Ha¨fner,
2000 ; Birchwood et al. 2000 ; Upthegrove et al. 2010).
Our results might also be interpreted as evidence
that depression in the acute phases does not have to
be exactly the same as depression in later phases of
schizophrenia. Patients in acute phases of schizo-
phrenia probably do not entirely realize that they need
help because of their contemporaneous delusions
and grandiosity. By contrast, depression implicates a
stronger urge to seek assistance and greater insight
into their illness, thereby leading them to a greater
recognition of those needs (Mintz et al. 2003 ;
Schennach-Wolﬀ et al. 2011). By the later phases,
working alliances might develop and patients may
learn to rate their need for treatment independently of
depressive symptoms. However, the missing impact
of insight revealed in our study discounts this hy-
pothesis.
Surprisingly, neither baseline positive nor negative
symptoms were relevant. However, at follow-up,
positive and negative symptoms and also functioning
diﬀered among the groups. One possible conclusion is
that neither psychotic symptoms nor depression and
functioning in acute phases could predict whether
patients would require more intensive help, especially
with social needs. Nevertheless, at follow-up there
may have been larger diﬀerences among patients
(i.e. whether they are in acute or stabilization phase of
illness), and therefore stronger eﬀects of psychopath-
ology. A more profound examination of the topic
would be interesting. For now, this lies beyond the
scope of our paper.
The prognosis of clinical improvement seemed to
discern the uncomplicated and complicated needs
course in patients with initially high numbers of un-
met needs. Thus, the prognosis was fairly exact be-
cause patients remaining high in unmet needs also
had more positive symptoms or lower functioning
scores at follow-up. However, our data did not clearly
indicate the basis upon which investigators drew their
conclusions concerning prognosis. There, an ad-hoc
scale was applied, for which psychometric properties
have not been ascertained. Despite the correct prog-
nosis at baseline, patients with a complicated needs
course had less frequent psychosocial interventions.
This could not have been explained as a failure to
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recognize their own needs because, at both baseline
and follow-up, those patients had indeed expressed
psychosocial needs. In general, the persistently high
occurrence of unmet social needs in patients with a
complicated course demonstrates the necessity to ad-
dress social and relationship needs during both
acute and post-acute phases of illness. Impairments in
(social) functioning can also be very stable in the
middle and late courses of schizophrenia (Ha¨fner et al.
1999). Antipsychotic treatment alone is not suﬃcient
to improve such functioning (Swartz et al. 2007). By
attending to unmet social needs at the early stages, the
progressive loss of meaningful relationships can be
prevented. Although we could not obtain information
about why those patients with many needs did not
receive help, these results indicate the importance of
studying the processes that lead to a clinical prognosis
and also the relationship between that prognosis and
treatment planning in ﬁrst-episode patients.
Whereas revealing more unmet needs at follow-up
coincided with better compliance, the opposite was
true at baseline. Using univariate analysis, we found
similar eﬀects of compliance at baseline and follow-
up. Therefore, compliance was better in patients with
more unmet needs later on, but only with regard to
other variables that were included in the follow-up
model.
Summary
The results from this study have demonstrated that, in
a sample of ﬁrst-episode patients, strong diﬀerences
were found among their 1-year courses of treatment
needs. An unfavourable course of unmet needs co-
incided with more positive symptoms. Psychosocial
treatment seemed to play a crucial role in inﬂuencing
the development of unmet needs. Whether in-
vestigators are able to predict those courses and
whether psychosocial treatment is responsible for
an improved needs course should be conﬁrmed by
studies that use more elaborate assessments. This may
identify those patients at risk for more unfavourable
courses, thereby prompting attention to reduce their
unmet needs.
Limitations
One limitation to the generalization of these results
was participants’ attrition. Our results are valid only
for patients who completed the study; it is unclear
whether the data would have been the same if all
patients had been included. We did not use impu-
tation of missing values because they were not ran-
domly distributed. Because unmet needs and several
other variables were predictors of missingness, such
imputation would have borne a high risk of biasing
the results.
A second limitation lay within the analytic strategy.
Low levels of unmet needs can be due to generally few
needs, but may also be a consequence of many needs
being met. The approach we used did not diﬀerentiate
between those conditions.
Other limitations were due to instruments and
study design. For example, the CAN is not devised
especially for ﬁrst-episode schizophrenia. If needs ex-
ist that are exclusively relevant in this phase of illness,
they may be missed by the CAN. Needs were assessed
during a controlled randomized trial that was aimed,
instead, at testing diﬀerent neuroleptic medications.
Other factors may have inﬂuenced the course of unmet
needs that were not addressed in this study.
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